Nanocrystalline TiO₂‑Catalyzed Photoreversible Color Switching

We report a novel photoreversible color switching system based on the photocatalytic activity of TiO₂ nanocrystals and the redox-driven color switching property of methylene blue (MB). This system rapidly changes from blue to colorless under UV irradiation and recovers its original blue color under visible light irradiation. We have identified four major competing reactions that contribute to the photoreversible switching, among which two are dominant: the decoloration process is mainly driven by the reduction of MB to leuco MB by photogenerated electrons from TiO₂ nanocrystals under UV irradiation, and the recoloration process operates by the TiO₂-induced self-catalyzed oxidation of LMB under visible irradiation. Compared with the conventional color switching systems based on photoisomerization of chromophores, our system has not only low toxicity but also significantly improved switching rate and cycling performance. It is envisioned that this photoreversible system may promise unique opportunities for many light-driven actuating or color switching applications

Forest plots of HR and 95%CI for disease-free survival / progress-free survival in ovarian cancer according to presence of HER2.

<p>Random-effects model was used.</p

The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies - Fig 6

<p><b>6A.</b> Begg’s publication bias plot of the studies assessing HER2 expression and overall survival in ovarian cancer. <b>6B.</b> Begg’s publication bias plot of the studies assessing HER2 expression and disease-free survival / progress-free survival in ovarian cancer. Visual inspection of the funnel plot did not identify substantial asymmetry.</p

Forest plots of HR and 95%CI for disease-free survival / progress-free survival in ovarian cancer according to presence of HER2.

<p>Random-effects model was used.</p

Forest plots of HR and 95%CI for overall survival in ovarian cancer according to presence of HER2.

<p>Random-effects model was used.</p

PRISMA flow chart of literature search and study selection.

<p>PRISMA flow chart of literature search and study selection.</p

Subgroup analyses of the relationship between HER2 expression and disease-free survival / progress-free survival of ovarian cancer.

<p>Subgroup analyses of the relationship between HER2 expression and disease-free survival / progress-free survival of ovarian cancer.</p

The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies - Fig 7

<p><b>7A.</b> Sensitivity analysis of 34 studies included in this meta-analysis for overall survival. <b>7B.</b> Sensitivity analysis of 14 studies included in this meta-analysis for disease-free survival / progress-free survival. Leave-one-out method was used to confirm the stability of the results.</p